These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26803355)

  • 1. Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.
    Savvidou S; Karatzidou K; Tsakiri K; Gagalis A; Hytiroglou P; Goulis J
    Diabetes Res Clin Pract; 2016 Mar; 113():125-34. PubMed ID: 26803355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Liu L; Yan H; Xia M; Zhao L; Lv M; Zhao N; Rao S; Yao X; Wu W; Pan B; Bian H; Gao X
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3292. PubMed ID: 31955491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
    Fan H; Pan Q; Xu Y; Yang X
    Arq Bras Endocrinol Metabol; 2013 Dec; 57(9):702-8. PubMed ID: 24402015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
    Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
    Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
    Bi Y; Zhang B; Xu W; Yang H; Feng W; Li C; Tong G; Li M; Wang X; Shen S; Zhu B; Weng J; Zhu D
    Acta Diabetol; 2014 Oct; 51(5):865-73. PubMed ID: 25118999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.
    Bunck MC; Cornér A; Eliasson B; Heine RJ; Shaginian RM; Wu Y; Yan P; Smith U; Yki-Järvinen H; Diamant M; Taskinen MR
    Atherosclerosis; 2010 Sep; 212(1):223-9. PubMed ID: 20494360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
    Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
    Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.